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Summary
PLO-SL (polycystic lipomembranous osteodysplasia
with sclerosing leukoencephalopathy) is a recessively in-
herited disorder characterized by systemic bone cysts and
progressive presenile frontal-lobe dementia, resulting in
death at !50 years of age. Since the 1960s, ∼160 cases
have been reported, mainly in Japan and Finland. The
pathogenesis of the disease is unknown. In this article,
we report the assignment of the locus for PLO-SL, by
random genome screening using a modification of the
haplotype-sharing method, in patients from a genetically
isolated population. By screening five patient samples
from 2 Finnish families, followed by linkage analysis of
12 Finnish families, 3 Swedish families, and 1 Norwe-
gian family, we were able to assign the PLO-SL locus to
a 9-cM interval between markers D19S191 and
D19S420 on chromosome 19q13. The critical region
was further restricted, to ∼1.8 Mb, by linkage-disequi-
librium analysis of the Finnish families. According to the
haplotype analysis, one Swedish and one Norwegian
PLO-SL family are not linked to the chromosome 19
locus, suggesting that PLO-SL is a heterogeneous dis-
ease. In this chromosomal region, one potential candi-
date gene for PLO-SL, the gene encoding amyloid pre-
cursor–like protein 1, was analyzed, but no mutations
were detected in the coding region.
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Introduction
PLO-SL (polycystic lipomembranous osteodysplasia
with sclerosing leukoencephalopathy; OMIM 221770
[http://www3.ncbi.nih.gov:80/htbin-post/Omim/disp
mim?221770])—also referred to by different combina-
tions of the eponym “Ja¨rvi-Hakola-Nasu disease” or as
“membranous lipodystrophy” or “brain-bone-fat dis-
ease”—is a rare recessively inherited disorder charac-
terized by systemic bone cysts and progressive presenile
frontal-lobe dementia (Hakola 1972, 1990). The first
patients were described in the 1960s, in Japan (Terayama
1961; Nasu et al. 1973) and in Finland (Ja¨rvi et al. 1968,
1995; Hakola 1972). Subsequently, ∼160 cases have
been reported, mainly in Japan (98 cases) and Finland
(32 cases) but also in Sweden (Adolfsson et al. 1978;
Nylander et al. 1996), Norway (Edvardsen et al. 1983),
the United States (Wood 1978; Bird et al. 1983), Italy
(Pazzaglia et al. 1986; Iannaccone et al. 1992; Preziuso
et al. 1992; Malandrini et al. 1996), South Africa (Stu¨-
bgen and Lotz 1992), Austria (Deisenhammer et al.
1993), Turkey (Koc¸er et al. 1994), and Belgium (Del-
dinne et al. 1996).
PLO-SL is characterized by a unique combination of
neuropsychiatric and skeletal symptoms (table 1) (Hak-
ola 1972, 1990). Clinical course is typical, with first
symptoms appearing in adolescence as pains and path-
ological fractures of bones of the extremities, followed
by progressive neurological deterioration culminating in
severe dementia and epileptiform seizures (Hakola 1972,
1990). Death occurs at !50 years of age. Radiological
examination of the skeleton is diagnostic for symmet-
rical cystlike lesions in the small bones of the extremities
and trabecular loss in the distal ends of the long tubular
bones (Ma¨kela¨ et al. 1982; Virtama et al. 1990). Cer-
ebral magnetic-resonance-imaging and computed-to-
mography scans reveal general diffuse brain atrophy,
which is accentuated in the frontal lobes; reduced white-
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Table 1
Typical Symptoms of PLO-SL
Age
(Years) Phase Major Symptoms
x13 Skeletal Pains in the ankles and
wrists; fractures in
the bones of the ex-
tremities, after a mi-
nor trauma
x25 Neuropsychiatric Frontal-lobe dementia;
agnostic-apractic-
aphasic symptoms;
lesion of the upper
motor neuron; gait
disturbance; my-
oclonic twitches; epi-
leptic seizures; atro-
phy of the optic discs
and retinae; urinary
incontinence; impo-
tence or frigidity
matter volume, with deep sulci; and bilateral calcifica-
tions in the basal ganglia (Iivanainen et al. 1984; Hakola
and Puranen 1993). Microscopically, bone cavities are
filled with characteristic convoluted membranocystic
structures, which are also observed in local adipose tis-
sue (Ja¨rvi et al. 1968; Nasu et al. 1973; Kitajima et al.
1989). Neuropathological symptoms, which are scat-
tered throughout the nervous system, include demyelin-
ation, axonal degeneration with spheroids, fibrillary
gliosis, calcospherites in basal ganglia, and thickening
of the walls of small venules and capillaries (Matsushita
et al. 1981; Sourander et al. 1981; Kalimo et al. 1994).
The pathogenesis of PLO-SL is unknown, but an im-
pairment in systemic lipid metabolism (Nasu et al. 1973)
and disturbance of glycolipid or glycoprotein metabo-
lism (Kitajima et al. 1989), as well as a defect in the
basement membranes of blood vessels (Ja¨rvi et al. 1968;
Kalimo et al. 1994), have been proposed.
The prevalence of PLO-SL is highest ( to61# 10
) in Finland (Hakola 1990), and the disease62 # 10
is considered to belong to the so-called Finnish disease
heritage, a group of ∼30 rare monogenic diseases that
are more common in Finland than elsewhere in theworld
(Norio et al. 1973). This disease group has its origins
in the special population history of Finland, which is
characterized by a small number of original settlers, rel-
ative isolation from the neighboring countries, and sub-
isolates formed within the remote parts of the country.
In all the Finnish diseases for which a gene defect has
been identified, one major mutation accounts for
90%–98% of the disease chromosomes (de la Chapelle
1993; Peltonen et al. 1995). These features make link-
age-disequilibrium–based methods highly useful for lo-
calization of disease genes in this population (Nikali et
al. 1995). In this study, we applied a modification of the
haplotype-sharing method to mapping of the PLO-SL
locus in the Finnish families, resulting in assignment of
the PLO-SL locus to chromosome 19q13 as well as ex-
clusion of this locus in one Norwegian and one Swedish
PLO-SL family.
Subjects and Methods
PLO-SL Families and DNA Samples
Blood and tissue samples from 12 Finnish families
segregating PLO-SL were collected for the genome
screen. Families B, D, F, G, H, K1, K2, M, and P are
described elsewhere, in the report by Hakola (1990), and
families Q, R, and S have not been described before (fig.
1). None of these families is known to have common
ancestors, but the majority of them originated in the
eastern central region of Finland (Hakola 1972, 1990).
In addition, samples from three Swedish PLO-SL fam-
ilies (U, V, and X in fig. 1), reported by Adolfsson et al.
(1978) and Nylander et al. (1996), and from one Nor-
wegian family (T in fig. 1), reported by Edvardsen et al.
(1983), were obtained. DNA was extracted from blood
samples, by use of a method modified from that de-
scribed by Blin and Stafford (1976) to adapt Phase Lock
Gel tubes (5 Primer3 Prime). DNA from paraffin-em-
bedded tissue samples was extracted as described by Is-
ola et al. (1994).
Blood or tissue samples were collected from the pa-
tients (or from the spouse and children if the patient was
deceased), their parents, and their siblings. Diagnosis of
PLO-SL was made on the basis of radiographic exam-
ination of limb bones, combined with analysis of typical
neuropsychiatric symptoms. Healthy siblings !40 years
of age were examined radiologically, to exclude undi-
agnosed cases. No new PLO-SL cases were found at this
phase. One asymptomatic sibling had a single bone le-
sion in her wrist. During the 5-year follow-up time, at
the end of which she was 40 years of age, she showed
no progression of bone changes and no symptoms of
frontal-lobe dementia. Therefore, she was scored as
healthy in the linkage analysis.
Samples were taken and clinical examinations were
performed in accordance with the Helsinki Declaration.
Participation was voluntary. Family members were told
in advance the possible outcomes of the clinical exam-
ination, and they could decide whether they wanted to
know the results. Samples from deceased individuals
were used by permission from the next of kin.
Marker Genotyping
Primers for the DNA markers used in the genome
screen were selected from the collection of primers from
Ge´ne´thon (Dib et al. 1996) or from the Cooperative
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Figure 1 PLO-SL pedigrees. Families B–S are Finnish in origin, and families B–P were described earlier by Hakola (1990). Family T is
from Norway and was reported by Edvardsen et al. (1983). Families U, V, and X originated in Sweden (Adolfsson et al. 1978; Nylander et al.
1996). Blackened symbols indicate PLO-SL patients. A “B” or a “T” beneath a symbol indicates an individual for whom blood or tissue samples,
respectively, were available. A number above a symbol indicates age at time of study or at death, for affected individuals, or age at time of
study, for unaffected siblings. Arrows indicate those PLO-SL patients whose samples were used in the genome screen using the haplotype-
sharing method.
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Human Linkage Center (CHLC) (Sheffield et al. 1995).
Chromosome 19 markers D19S609, D19S610,
D19S608, MK4, and MK5 had been developed by us
(Ma¨nnikko¨ et al. 1995; Kestila¨ et al., in press), and
marker D19S191 was selected from the Genome Da-
tabase (accession number GDB:181997 [http://
www.gdb.org/]). Primers for the CHLC markers were
purchased from the Nordic Human Genome Initiative,
and one of the primers was labeled with cy5, during
synthesis. Primers for other markers either were pur-
chased from Ge´ne´thon or were synthesized at the Na-
tional Public Health Institute, by use of the 394 DNA/
RNA Synthesizer (Applied Biosystems). If none of the
primers was cy5 labeled, one of them was end labeled
with 32P. The PCR reactions were performed in a 15-ml
reaction volume containing 20 ng genomic DNA, 4–5
pmol both primers, 0.2 mM dNTP, 1.5 mM MgCl2, 10
mM Tris-HCl, 50 mM KCl, 0.1% Triton X-100, and
0.15 U DynaZyme (Finnzymes Oy). PCRwas performed
for 30–35 cycles of annealing for 30 s at a specific tem-
perature for each primer pair, extension for 30 s at 72C,
and denaturation for 30 s at 95C, after an initial de-
naturation for 3 min at 95C, in multiwell microtiter
plates in programmable thermal controllers (MJ Re-
search or Hybaid OmniGene). PCR products were size
separated, by PAGE, on either conventional sequencing
apparatus (32P label) or on an ALF express (cy5 label;
Pharmacia). The radioactive gels were vacuum dried and
autoradiographed overnight by use of KodakX-OMATS
film. Allele data from the ALF express were printed as
fluorescence curves. The alleles were scored by eye and
were entered into a database file during the initial stage
of the genome screen and into a linkage file during the
second stage.
SSCP Analysis of the APLP1 Gene
The sequence for chromosome 19 cosmid R28051,
which contains the gene for amyloid precursor–like pro-
tein 1 (APLP1; Wasco et al. 1992, 1993), has been re-
ported in the Genome Sequence Database (GSDB:S:
1117815 [http://ncgr.org/gsdb/gsdb.html]). The exonic
sequences of APLP1 were screened for mutations in the
PLO-SL patients, by use of the SSCP method (Orita et
al. 1989; Glavac and Dean 1993). Intronic primers for
the 17 exons of APLP1 were designed (Lenkkeri et al.,
in press). Exons were amplified by PCR in a 50-ml re-
action volume containing 50 ng genomic DNA, 50 pmol
primers, 0.2 mM dNTP, 0.2 ml a-[32P]-ATP, 1.5 mM
MgCl2, 10 mM Tris-HCl, 50 mM KCl, 0.1% Triton X-
100, 10% glycerol, and 0.5 U DynaZyme (Finnzymes
Oy). PCR was performed for 30–35 cycles of annealing
for 1 min at a specific temperature for each primer pair,
extension for 1 min at 72C, and denaturation for 1 min
at 95C, after an initial denaturation for 5 min at 95C,
in a thermal controller (MJ Research). PCR products
were run on nondenaturing 5% polyacrylamide gels, at
30-W constant power for 5 h in a cold room and at 10-
W constant power, with 10% glycerol, for 15 h at room
temperature (Glavac and Dean 1993). The gels were
vacuum dried and autoradiographed. Migration of sam-
ples from two Finnish patients and from controls were
compared.
Statistical Analyses
Linkage analysis was performed by use of the LINK-
AGE package (Lathrop and Lalouel 1984; Lathrop et
al. 1984, 1986), and heterogeneity analysis was per-
formed by use of the program HOMOG (Ott 1986).
Analysis was performed by use of a recessive-inheritance
model (Hakola 1972). The disease-gene frequency was
set to .001 for the Finnish population. Age-dependent
penetrance classes were constructed on the basis of age
at diagnosis of the Finnish patients (Ott 1991). The me-
dian age at diagnosis was 34 years. Penetrance was set
to 0 for individuals !21 years of age, to .30 for indi-
viduals 21–34 years of age, to .80 for individuals 35–49
years of age, and to 1.00 for individuals x50 years of
age. No phenocopies were allowed. Since children of
affected individuals had not been radiologically studied,
their disease status was set as unknown, for the linkage
analysis, and marker data were used only to reconstruct
the genotype of their affected parent. Allele frequencies
for DNA markers were calculated from analysis of the
family material. The order and genetic and physical dis-
tances between chromosome 19q13 markers were taken
from the Ge´ne´thon map (Dib et al. 1996), the published
physical map for chromosome 19 (Ashworth et al.
1995), and our previous studies (Ma¨nnikko¨ et al. 1995;
Kestila¨ et al., in press).
Linkage-disequilibrium analyses were performed by
use of the programs HRRLAMB and HRRMULT (Ni-
kali et al. 1995; Terwilliger 1995, 1996). These pro-
grams apply a likelihood-ratio test for linkage disequi-
librium (Terwilliger 1995, 1996) to the haplotype-based
“haplotype relative-risk” approach (Falk andRubinstein
1987; Terwilliger and Ott 1992). The advantage of this
statistic is that it has only 1 df, irrespective of the number
of markers or the number of alleles of the marker. As a
result, when multiallelic markers or multiple markers are
analyzed jointly, this statistic becomes more powerful
than that of conventional x2 analysis. In multipoint as-
sociation analysis, the recombination fraction (v) be-
tween marker loci is kept fixed, and the likelihood is
maximized over a (the proportion of disease alleles orig-
inally associated with a certain allele) and n (the number
of generations since introduction of the founder disease
allele into the population).
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Table 2
Chromosome 19 Genotypes for the First Stage of the Genome Screening
MARKER
GENETIC
DISTANCE
TO NEXT
MARKER
(cM)
GENOTYPE
Family P Family S
Patient 1 Patient 2 Patient 1 Patient 2 Patient 3
D19S215 3 4-5 4-5 4-7 3-4 4-7
D19S882 5 3-4 3-4 3-3 3-3 3-3
D19S225 7 3-5 3-4 3-3 3-3 3-3
D19S422a 4 2-5 2-5 5-5 5-5 5-5
D19S420 2 1-5 1-5 2-2 2-2 2-2
D19S217 2 2-2 2-2 6-6 6-6 6-6
D19S412 5 3-7 3-7 7-7 7-7 7-7
D19S907 1 2-3 2-3 2-2 2-2 2-2
D19S246 1 2-3 2-3 1-2 1-2 1-2
KLK1 4-4 4-4 3-4 4-4 4-4
a Localizes to the PLO-SL critical region bordered by recombinations in the markers
D19S191 and D19S420.
Table 3
Results from the Linkage Analysis of the
Scandinavian PLO-SL Families
Marker LODHom
a LODHet
b
D19S208 .05 .32
D19S191 .87 1.34
D19S609 .51 .61
MK4 5.59 5.79
MK5 2.29 2.97
D19S610 4.70 5.40
D19S608 3.69 4.46
D19S224 2.86 3.92
D19S896 3.09 3.19
D19S228 2.04 2.04
D19S421 .24 .47
D19S422 2.67 3.68
D19S223 .54 .86
D19S420 .71 .75
D19S217 1.25 1.26
a Maximum LOD score under homo-
geneity.
b Maximum LOD score under hetero-
geneity.
Results
Genome Screen
The genome screen to locate the defective gene for
PLO-SL was performed in two stages. In the first stage,
DNA samples from five affected siblings (indicated by
arrows in fig. 1), from Finnish families P and S, were
analyzed by use of polymorphic DNA markers, to iden-
tify genomic regions showing haplotype sharing. In the
second stage of the screening, the markers that were in
regions where the initial screening showed haplotype
sharing among siblings, in both families, were genotyped
in a panel of 10 PLO-SL families (D, F, G, H, K1, K2,
P, Q, R, and S in fig. 1).
Altogether, 592 DNA markers where genotyped in the
sibships P and S, resulting in an approximate map den-
sity of 6 cM. For six genomic regions, both sibships
showed haplotype sharing within the family, at two or
more adjacent markers. For chromosome 2q37, siblings
shared haplotypes of eight markers in an 18-cM region.
On chromosome 19q13, sharing extended over six
markers in a 14-cM region (table 2). In four regions on
chromosomes 1, 4, 5, and 21, haplotype sharing ex-
tended to a maximum of 10 cM.
At the second stage, markers in these and some ad-
ditional regions were genotyped in a panel of 10 PLO-
SL families. A total of 156 markers were analyzed by
linkage analysis of these families. One marker on chro-
mosome 2q37 gave a significant LOD score 13, in the
linkage analysis. Six markers, on chromosomes 2q37
and 19q13, gave LOD scores 12, and an additional 11
markers, in six chromosomal regions (on chromosomes
1, 2q37, 4, 10, 19q13, and 21), gave LOD scores 11.
The promising regions on chromosomes 2q37 and
19q13 were selected for further study with the complete
family sample and additional markers, after which only
markers on 19q13 continued to provide significant ev-
idence for linkage.
Assignment of the PLO-SL Locus to 19q13
Results of the linkage analysis of the markers on chro-
mosome 19q13 are shown in tables 3 and 4. When all
the Scandinavian families were analyzed together, sig-
nificant evidence for linkage to severalmarkers on 19q13
was detected, with a maximum LOD score of 5.59 for
marker MK4, at (table 3). Two markers,v  .02
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Table 4
Results from the Linkage and Association Analyses of the Finnish PLO-SL Families
MARKER
LOD SCORE AT v 
x2 LRT a
P
VALUE lb.00 .01 .05 .1 .2
D19S208  .11 .65 .72 .54 .00000 .500000 .000000
D19S191  1.39 1.81 1.72 1.20 1.32827 .124547 .749818
D19S609 .98 .98 .96 .89 .69 .00000 .500000 .000000
MK4 6.28 6.10 5.36 4.45 2.75 10.55326 .000583 .750131
MK5 4.71 4.58 4.04 3.38 2.12 1.11148 .145872 .599820
D19S610 6.37 6.19 5.44 4.53 2.83 20.96025 .000002 .943770
D19S608 5.08 4.91 4.26 3.48 2.07 13.36223 .000129 .883339
D19S224 5.12 4.97 4.36 3.62 2.25 15.44040 .000043 1.000000
D19S896 4.67 4.55 4.03 3.38 2.12 6.80221 .004561 .774917
D19S228 1.50 1.46 1.28 1.06 .65 .00000 .500000 .000000
D19S421 1.76 1.72 1.56 1.33 .87 13.50329 .000120 1.000000
D19S422 3.42 3.35 3.01 2.55 1.60 .00000 .500000 .000000
D19S223 2.01 1.98 1.82 1.59 1.05 .00000 .500000 .000000
D19S420  .31 1.09 1.28 1.07 .00000 .500000 .000000
D19S217 1.85 1.85 1.80 1.64 1.17 .00000 .500000 .000000
a The x2 statistic of the likelihood-ratio test (Terwilliger 1995, 1996).
b The proportion of excess of a certain allele in the chromosomes carrying the PLO-
SL gene.
D19S224 and D19S422, gave significant evidence for
linkage only when heterogeneity was allowed. All mark-
ers gave higher LOD scores under heterogeneity (table
3), but none of them revealed statistically significant ev-
idence for heterogeneity.
When the Finnish families were analyzed separately,
no evidence for locus heterogeneity was obtained. All
markers in a 17-cM region showed evidence for linkage,
with a maximum LOD score of 6.37, to marker
D19S610 (table 4). The critical region was bordered by
obligatory recombinations, observed with markers
D19S191 and D19S420, which are separated by 9 cM
(Ashworth et al. 1995; Dib et al. 1996).
When chromosome 19 markers were analyzed in the
Swedish and Norwegian families, no evidence for link-
age or for heterogeneity was obtained. All the markers,
except for D19S228, which was uninformative in the
families, showed exclusion of linkage to 19q13 (LOD
score !2 at ). Haplotype analysis of 19q13v  .00
markers in these families revealed clear nonsegregation
in Norwegian family T (fig. 2) and in Swedish family X,
whereas linkage to chromosome 19 markers could not
be excluded in two other Swedish families (U and V in
fig. 1).
Linkage-Disequilibrium Analysis of the Finnish PLO-SL
Families
The results of the linkage-disequilibrium analysis of
the Finnish PLO-SL families are shown in table 4. Several
markers in a 3-cM region between markers MK4 and
D19S421 showed evidence for allelic association in the
PLO-SL chromosomes (Ashworth et al. 1995; Ma¨n-
nikko¨ et al. 1995; Dib et al. 1996; Kestila¨ et al., in press).
Data from all markers were combined in the multipoint
association analysis, by use of the program HRRMULT
(Terwilliger 1995, 1996). The peak of the likelihood
curve was reached between markers D19S610 and
D19S224, within the vicinity of marker D19S608, with
, which had a P value of !1015 (fig. 3). The2x  67.3
estimated a value was 1.00.
SSCP Analysis of the APLP1 Gene
The gene for APLP1 (Wasco et al. 1992, 1993) is
located within the vicinity of marker D19S610 (Ma¨n-
nikko¨ et al. 1995), the alleles of which show the highest
linkage disequilibrium with the PLO-SL chromosomes.
Even though the physiological function of the gene prod-
uct is not known, this gene was considered to be an
interesting candidate for PLO-SL, because of its ho-
mology to the amyloid-precursor protein (APP) that is
defective in a subgroup of Alzheimer patients. The
APLP1 gene is ∼10.8 kb and codes for 17 exons (Lenk-
keri et al., in press). Intronic primers for all exons were
designed, and the exons were amplified, by PCR, from
two Finnish PLO-SL patients and two healthy individ-
uals. Differences in the mobility of the SSCP bands, be-
tween patients and controls, were searched under two
running conditions, but none were detected.
Discussion
Similarity Search
In this study, we assigned the locus for PLO-SL to
chromosome 19q13, using a modification of the hap-
lotype-sharing method. In the haplotype-sharing
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Figure 2 Chromosome 19 haplotypes for Norwegian PLO-SL
family T. Marker order (top to bottom) is as follows: D19S208,
D19S191, D19S609, MK4, MK5, D19S610, D19S608, D19S224,
D19S896, D19S228, D19S421, D19S422, D19S223, D19S420, and
D19S217. Blackened symbols indicate PLO-SL patients, and a number
above a symbol indicates age at time of study.
Figure 3 Multipoint association analysis of chromosome 19
markers, for the Finnish PLO-SL families.
method, chromosome segments shared identical-by-de-
scent (IBD) by affected individuals, owing to linkage
disequilibrium, are used to locate a disease gene (Hou-
wen et al. 1994). The usefulness of this method depends
on the degree of heterogeneity and on the distance of
the relationship between the affected individuals. When
these factors increase, more samples and a densermarker
map are required (Houwen et al. 1994; Meerman et al.
1995). As a result, the haplotype-sharing method has
been adopted mainly for the analysis of affected indi-
viduals from homogeneous populations who are known
to be related (Houwen et al. 1994; Nikali et al. 1995).
In Finland, most of the rare recessive diseases are caused
by one major mutation descending from a single founder
chromosome (de la Chapelle 1993; Peltonen et al. 1995).
The size of the region where linkage disequilibrium is
detected in disease chromosomes varies by 2–13 cM (Pel-
tonen et al. 1995). In our study, the two sibships ana-
lyzed in the first stage of the genome screening were not
known to be related, and, consequently, a map as dense
as 2 cM would have been required to detect linkage
disequilibrium. Therefore, we did not try to identify a
haplotype shared by all five affected individuals, but,
rather, we tried to pinpoint for further analysis those
genomic regions in which both sibships would show ex-
tensive haplotype sharing. Terwilliger et al. (1997) have
shown that patients tend to share segments IBD that
overlap the disease gene and that are larger than would
be expected to occur by chance. Six times during the
genome screening, the five affected siblings in the two
Finnish sibships shared marker genotypes at two ormore
adjacent markers simultaneously. Only two chromoso-
mal regions showed extensive haplotype sharing at a
110-cM region, of which one was found to be linked to
PLO-SL. As was expected, we did not find a conserved
haplotype shared by all affected individuals during the
first stage of the genome screening (table 2), since this
conserved haplotype was too short (3 cM) to be detected
with our map density.
Heterogeneity of PLO-SL
Our extensive genome screening, heterogeneity anal-
ysis, and haplotype analysis of the Norwegian and Swed-
ish families suggest that PLO-SL is a heterogeneous dis-
ease. Our primary assumption was that all the
Scandinavian families would be linked to the same locus.
This seemed especially valid with respect to the Swedish
families, since all the Swedish PLO-SL families origi-
nated in northern Sweden, where the Finnish influence
has been strong. Northern Sweden has received several
waves of immigration from Finland, and it has been
estimated that 60%–80% of the gene pool is Finnish in
origin (Nylander and Beckman 1991). The ancestors of
two families (U and V in fig. 1) could actually be traced
back to Finland (Nylander et al. 1996). According to
our haplotype analysis, the Norwegian family and the
Swedish family not originating directly from Finland (X
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in fig. 1) are not linked to the chromosome 19 locus.
On the other hand, we cannot exclude linkage to chro-
mosome 19 in Swedish families U and V, which are
known to have Finnish ancestors. Unfortunately, the
analysis of the two unlinked families, T and X, did not
have enough power to detect linkage alone. When the
mutation in the Finnish PLO-SL families is identified, it
might be possible to search for members with the same
metabolic pathway or gene family, to identify the gene
defect in the unlinked families as well.
Locus Restriction by Linkage Disequilibrium
The critical region for PLO-SL is bordered by recom-
binations in markers D19S191 and D19S420, which are
separated by 9 cM (fig. 3) (Ashworth et al. 1995; Dib
et al. 1996). This region on chromosome 19q13.1, har-
boring tens of genes, is one of the most gene-rich regions
in the whole human genome (Schuler et al. 1996). Clon-
ing of the PLO-SL gene from this region would be an
exhausting task. However, linkage disequilibrium in the
Finnish PLO-SL families was detected only with markers
in the region extending from MK4 to D19S421, restrict-
ing the area to a maximum of 3 cM (fig. 3). Physically,
this distance corresponds to ∼1.8 Mb (Ashworth et al.
1995; Ma¨nnikko¨ et al. 1995; Dib et al. 1996; Kestila¨ et
al., in press), which is already feasible for transcriptmap-
ping and even for direct sequencing.
Candidate Genes in the Critical Region
Within the 3-cM region between markers MK4 and
D19S421, at least seven genes are known to exist (Ash-
worth et al. 1995): the genes for the a-polypeptide of
the H/K-transporting ATPase (ATP4A; Maeda et al.
1990), cytochrome c oxidase subunit VIB (COX6B;
Taanman et al. 1989), muscle-specific polypeptide 1 of
cytochrome c oxidase subunit VII (COX7A1; Fabrizi et
al. 1989), amyloid precursor–like protein 1 (APLP1;
Wasco et al. 1992, 1993), and the small polypeptide of
calpain (CANPS; Ohno et al. 1986). ATP4A is found in
gastric parietal cells and is responsible for acid secretion
in the stomach. Cytochrome c oxidase forms complex
IV of the mitochondrial respiratory chain, the defects of
which are associated with chronic lactic acidemia and
myopathy or multiorgan syndrome (De Vivo 1993). Lac-
tic acidosis has not been reported in the PLO-SL patients
(Hakola 1972, 1990). APLP1 and CANPS appear to be
the more interesting candidates for PLO-SL.
APLP1 was cloned in 1992 (Wasco et al. 1992, 1993),
on the basis of its homology to APP, which is the source
of the bA4-peptide forming the major component of the
core of amyloid plaques in Alzheimer disease. APLP1
belongs to a conserved APP gene family, members of
which also have been cloned from mouse, rat, and dro-
sophila. There are few studies on the biological function
of APLP1, but mouse APLP1 exhibits brain-specific ex-
pression and is localized to postsynaptic density of the
synapse (Kim et al. 1995). Therefore, it is hypothesized
to play a role in brain synaptic function (Kim et al.
1995). The expression of APLP1 in bone tissue has not
been investigated. We studied the exonic sequences of
the APLP1 gene, by SSCP analysis, and did not detect
mobility differences between the samples from the Finn-
ish PLO-SL patients and those from controls. The sen-
sitivity of SSCP analysis varies by 50%–98%, depending
on the sequence and the SSCP conditions (Glavac and
Dean 1993). In our laboratory, the sensitivity has been
as high as 98% (Ikonen et al. 1991; Kauppinen 1992).
However, we cannot exclude the possibility of a con-
formationally silent mutation in the coding sequences or
of a mutation in the noncoding sequences, such as the
introns and the 5′ regulatory regions.
Another interesting gene in the PLO-SL region is
CANPS, the gene for the small regulatory subunit of
calcium-dependent cysteine proteinase (Ohno et al.
1986). Calpain has been shown to mediate the parathy-
roid-hormone induced osteoblastic retraction (Tram et
al. 1993), and calpain activation has been proposed to
affect long-term potentiation of memory as well as neu-
ropathological processes such as transient ischemia-in-
duced neurodegeneration and Alzheimer disease (Suzuki
et al. 1995). Therefore, as a candidate for PLO-SL,
CANPS also warrants further study.
Significance of the PLO-SL Gene
PLO-SL belongs to a clinically and genetically heter-
ogeneous group of degenerative dementias (Miller
1997), but it is unique because of its combination of
dementia and bone cysts. The PLO-SL locus does not
overlap with any other locus reported for degenerative
dementias. Genetic loci for other frontotemporal de-
mentias, which usually are dominantly inherited and
have a typical age at onset of senilium, have been re-
ported on chromosomes 3 (Brown et al. 1995) and 17
(Wilhelmsen et al. 1994; Wijker et al. 1996; Yamaoka
et al. 1996). Another dementia gene, Notch3—which is
defective in CADASIL (cerebral autosomal dominant ar-
teriopathy with subcortical infarcts and leukoencephal-
opathy), a hereditary adult-onset condition causing
stroke and dementia—also localizes to chromosome 19
but is on the p arm (Joutel et al. 1996).
Even though PLO-SL is a rare disease, it deserves spe-
cial attention because some of its symptoms and path-
ological features resemble those of common diseases,
such as Alzheimer disease, vascular and other dementias,
and major psychoses. It also has been suggested that
PLO-SL is incompletely recessive, since single bone cysts
also have been found in otherwise clinically healthy sib-
lings of the PLO-SL patients (Hakola 1972). Investiga-
370 Am. J. Hum. Genet. 62:362–372, 1998
tion of whether one copy of the PLO-SL gene renders
carriers more susceptible to common diseases, such as
common dementias and major psychoses, would be
worthwhile.
There is a long latent period between the early skeletal
and the incapacitating neuropsychiatric symptoms of
PLO-SL, which can be as long as 20 years. At present,
there is no curative treatment available for patients who
are diagnosed in the relatively asymptotic skeletal phase.
Cloning of the defective gene could make it possible to
interfere in the neurodegenerative process and prevent
the deterioration.
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